Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biotron Limited ( (AU:BIT) ) has shared an announcement.
Biotron Limited has appointed the USA-based C14 Consulting Group LLC to assist in forming strategic partnerships for its antiviral programs, including its lead clinical asset BIT225. This collaboration aims to refine Biotron’s commercialization strategy, leveraging C14’s extensive network and expertise in the pharmaceutical industry. The company is focused on achieving commercial outcomes from its antiviral programs, supported by recent data from three Phase 2 clinical trials. Biotron continues to advance its anti-HBV compounds, which have shown significant antiviral activity in preclinical studies, addressing a critical global health issue. During the quarter, two Non-Executive Directors retired, and financial expenditures on research and development were disclosed.
More about Biotron Limited
Biotron Limited operates in the pharmaceutical industry, focusing on developing antiviral programs targeting a range of viruses. Its primary product portfolio includes viroporin antagonists, which uniquely combine direct-acting antiviral and immunomodulatory activities. The company is actively involved in developing treatments for HIV-1, SARS-CoV-2, Hepatitis B virus (HBV), influenza, Dengue virus, and others.
YTD Price Performance: 0.0%
Average Trading Volume: 27,244
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.04M
See more insights into BIT stock on TipRanks’ Stock Analysis page.